MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Shire PLC Company Profile (NASDAQ:SHPG)

Consensus Ratings for Shire PLC (NASDAQ:SHPG) (?)
Ratings Breakdown: 2 Hold Rating(s), 23 Buy Rating(s)
Consensus Rating:Buy (Score: 2.92)
Consensus Price Target: $238.29 (31.90% upside)

Analysts' Ratings History for Shire PLC (NASDAQ:SHPG)
Show:
DateFirmActionRatingPrice TargetActions
6/28/2016Goldman SachsReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/16/2016Leerink SwannReiterated RatingBuy$225.00 -> $213.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/15/2016RBC CapitalReiterated RatingOutperformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/14/2016Shore CapitalReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/13/2016Piper JaffrayReiterated RatingNeutral$174.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/9/2016Sanford C. BernsteinReiterated RatingOutperform$222.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/3/2016Jefferies GroupBoost Price TargetBuy$223.00 -> $262.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/3/2016Morgan StanleyReiterated RatingOverweightView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/26/2016Stifel NicolausInitiated CoverageBuy$230.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/23/2016Bryan, Garnier & CoInitiated CoverageBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/22/2016JPMorgan Chase & Co.Reiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/6/2016Liberum CapitalInitiated CoverageBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/3/2016Cowen and CompanyReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/12/2016BTIG ResearchReiterated RatingBuy$230.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/30/2016Bank of AmericaReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/26/2016Cantor FitzgeraldInitiated CoverageBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/13/2016Northland SecuritiesReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/9/2016GuggenheimInitiated CoverageNeutralView Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/8/2016SusquehannaLower Price TargetPositive$280.00 -> $220.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/18/2016Credit SuisseUpgradeBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/18/2016BNP ParibasUpgradeNeutral -> OutperformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/3/2015HSBCUpgradeHold -> BuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/21/2015William BlairReiterated RatingOutperform$276.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/21/2015BarclaysUpgradeEqual Weight -> OverweightView Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/16/2015Berenberg BankInitiated CoverageBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/8/2015Deutsche BankReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/9/2015Citigroup Inc.Reiterated RatingBuy$285.53View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/6/2015Kepler Capital MarketsReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/12/2015S&P Equity ResearchDowngradeStrong-Buy -> BuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/5/2015Panmure GordonReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/27/2014CRT CapitalReiterated RatingBuy$225.00 -> $233.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/20/2014SunTrustUpgradeNeutral -> Buy$269.00 -> $225.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/22/2014Buckingham ResearchDowngradeNeutralView Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/30/2014 forward)
Earnings History for Shire PLC (NASDAQ:SHPG)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
4/29/2016Q1$3.05$3.19$1.71 billion$1.71 billionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/11/2016Q415$2.89$2.97$1.69 million$1.72 billionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/23/2015Q315$2.87$3.24$1.63 billion$1.58 billionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/23/2015Q215$2.81$2.63$1.59 billion$1.56 billionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/30/2015Q115$2.56$2.84$1.47 billion$1.49 billionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/12/2015Q115$2.68$2.63$1.58 billionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/24/2014Q314$2.47$2.93$1.46 billion$1.55 billionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/18/2014Q214$2.45$2.67$1.45 billion$1.50 billionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/1/2014Q114$2.22$2.36$1.38 billion$1.35 billionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/13/2014Q413$2.02$2.26$1.28 billion$1.33 billionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/24/2013Q213$1.65$1.77$1.23 billion$1.24 billionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/25/2013$1.60$1.79$1.21 billion$1.28 billionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/2/2013Q113$1.56$1.63$1.21 billion$1.16 billionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/14/2013Q412$1.58$1.58$1.20 billion$1.20 billionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/25/2012$1.47$1.36ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/1/2012$1.52$1.68ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/26/2012$0.52$1.24ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/9/2012$0.48$0.44ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/28/2011$1.31$1.28ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/28/2011$1.24$1.33ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/28/2011$1.18$1.23ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/10/2011$1.04$1.03ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for Shire PLC (NASDAQ:SHPG)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20167$2.76$3.17$3.01
Q2 20166$3.02$3.23$3.10
Q3 20164$3.12$3.32$3.20
Q4 20164$3.13$3.48$3.34
(Data provided by Zacks Investment Research)
Dividend History for Shire PLC (NASDAQ:SHPG)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable DateShare
2/11/2016$0.673/9/20163/11/20164/12/2016Tweet This Announcement  Share This Announcement on StockTwits
7/23/2015$0.139/2/20159/4/201510/2/2015Tweet This Announcement  Share This Announcement on StockTwits
2/23/2015semiannual$0.570.48%3/11/20153/13/20154/14/2015Tweet This Announcement  Share This Announcement on StockTwits
8/4/2014semiannual$0.110.09%9/3/20149/5/201410/3/2014Tweet This Announcement  Share This Announcement on StockTwits
2/20/2014semiannual$0.510.61%3/5/20143/7/20144/8/2014Tweet This Announcement  Share This Announcement on StockTwits
7/29/2013semiannual$0.090.16%9/4/20139/6/201310/3/2013Tweet This Announcement  Share This Announcement on StockTwits
2/19/2013semiannual$0.440.92%3/6/20133/8/20134/9/2013Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2013 forward)
Insider Trading History for Shire PLC (NASDAQ:SHPG)
No insider trades for this company have been tracked by MarketBeat.com

Latest Headlines for Shire PLC (NASDAQ:SHPG)
DateHeadline
06/29/16 06:18 PMShire PLC (SHPG) Takes a Drug-Induced Bounce
06/29/16 11:37 AM[$$] Shire Reports Encouraging Results for ADHD Drug -
06/29/16 09:08 AMShire's SHP465 shows positive effect in adults with ADHD in late-stage study; NDA resubmission set for year end
06/29/16 09:08 AMShire's (SHPG) SHP465 Efficacy and Safety Study Met Primary Endpoints in Adults with ADHD
06/29/16 08:41 AMShire Announces Positive Topline ... - [at noodls] - June 29, 2016 Topline results revealed the study met its primary endpoints for both doses of SHP465 (12.5mg and 37.5mg) administered once daily, indicating superiority over placebo in ADHD symptom improvement ...
06/29/16 07:15 AMShire says ADHD drug meets main goal of study - [Reuters] - Irish drugmaker Shire Plc said a study testing an experimental drug to treat attention-deficit disorder met the main goal, bringing the drug one step closer to approval in the United States. The company's shares were up 3 percent at 4381 pence at 12.52 GMT on the London Stock Exchange on Wednesday. Shire's U.S.-listed shares were up 3 percent at $176.28 in light premarket trading on the Nasdaq.
06/29/16 06:12 AMShire's stock surges after ADHD drug trial meets key endpoints -
06/29/16 06:01 AM7:01 am Shire announces positive topline results of SHP465 efficacy and safety study in adults with ADHD; Shire plans to file a Class 2 Resubmission of the New Drug Application (:NDA) with the FDA by the end of 2016 -
06/29/16 06:00 AMShire Announces Positive Topline Results of SHP465 Efficacy and Safety Study in Adults With ADHD - [PR Newswire] - Shire plc (LSE: SHP, NASDAQ: SHPG) today announced positive topline results from a four-week randomized, double-blind, multicenter, parallel-group, placebo-controlled, forced-dose titration, efficacy and safety study, SHP465-306, in 275 adults aged 18-55 years with Attention-Deficit/Hyperactivity Disorder (ADHD). SHP465 (triple-bead mixed amphetamine salts - MAS) is an investigational oral stimulant medication being evaluated in the U.S. as a potential treatment for ADHD, a therapeutic area with significant need for additional treatment options. The primary efficacy analysis of study 306 showed that SHP465 12.5mg and 37.5mg, both administered as a daily morning dose, were superior to placebo with respect to the change from baseline on a clinically administered ADHD rating scale (ADHD-RS) total score, with Least Squares mean differences from placebo at Week 4 of -8.1 (95% CI: -11.7 to -4.4, p<0.001) for 12.5mg, and -13.3 (95% CI: -17.0 to -9.6, p<0.001) for 37.5mg.
06/25/16 10:06 AMAnalyst's Overview of Two Stocks: Rock Creek Pharmaceuticals, Inc. (PNK:RCPI) , Shire plc (NASDAQ:SHPG) - Street Updates
06/25/16 10:06 AMHC Stocks to watch for: ImmunoGen, Inc. (NASDAQ:IMGN), Shire PLC (ADR) (NASDAQ:SHPG) - share market updates (press release)
06/25/16 10:06 AMTwo Movers inside Analysts Radar: Shire plc (NASDAQ:SHPG) , ConforMIS, Inc. (NASDAQ:CFMS) - Street Updates
06/24/16 06:30 PMSpecialty Pharmaceuticals Brexit Risk 'Minimal' - Guggenheim (AGN) (ENDP) (MYL) (VRX) (more...)
06/23/16 07:06 PMShire plc (NASDAQ:SHPG) Analyst Rating Consensus - Trade Calls
06/23/16 09:01 AMStrong Buy Calls Count For Shire plc (NASDAQ:SHPG) At 10 - Investor Newswire
06/22/16 06:20 PMShire PLC (ADR) (NASDAQ:SHPG): Continue to Grow - Street Report
06/22/16 08:07 AMWhat Is Shire’s Outlook for 2016? -
06/21/16 02:23 PMWill Lifitegrast Be Approved in 2016? -
06/18/16 10:27 AMShire is Now Oversold (SHPG)
06/17/16 09:03 AMNoteworthy Analysts Suggestions: Rock Creek Pharmaceuticals, Inc. (PNK:RCPI) , Shire plc (NASDAQ:SHPG) - Street Updates
06/16/16 10:47 AMAnalysts Watch-list Stocks: Johnson & Johnson (NYSE:JNJ) , Shire plc (NASDAQ:SHPG) - Street Updates
06/16/16 10:47 AMIntrexon Corp (NYSE:XON) & Shire PLC (ADR) (NASDAQ:SHPG) Healthcare Movers to Watch - Wall Street 24
06/15/16 04:19 PMShire Buys Global Rights to Pfizer's Gastrointestinal Drug -
06/15/16 02:25 PM[$$] Allergan, Teva Set to See Catalysts -
06/15/16 10:52 AMBlazing Stocks Calls Bulls- Shire plc (NASDAQ:SHPG), Johnson Controls (NYSE:JCI), Merck & Co. (NYSE:MRK) - Seneca Globe
06/15/16 10:52 AMEarnings Overview: Ball Corporation (NYSE:BLL), Shire plc (NASDAQ:SHPG) - Beacon Chronicle
06/15/16 10:52 AMShire PLC (ADR) (NASDAQ:SHPG) Acquires Rights to Pfizer, Inc. (NYSE:PFE) IBD Drug - Market Exclusive
06/14/16 06:03 PMShire to License PF-00547659 from Pfizer, Adding to Established and Leading Gastrointestinal Portfolio
06/14/16 05:18 PMShire Gets Breakthrough Status for Rare Disease Candidates -
06/14/16 11:09 AMPrice Target Estimates: Shire plc (NASDAQ:SHPG) - News Oracle
06/14/16 11:09 AMStocks Earnings Overview: FireEye, Inc. (NASDAQ:FEYE), Shire plc (NASDAQ:SHPG) - Beacon Chronicle
06/14/16 11:09 AMHC Stocks Alerts: Shire PLC (ADR) (NASDAQ:SHPG), Novartis AG (ADR) (NYSE:NVS) - share market updates (press release)
06/14/16 11:09 AMAnalyst Suggestions Overview: Lululemon Athletica Inc. (NASDAQ:LULU), Shire plc (NASDAQ:SHPG) - Beacon Chronicle
06/14/16 11:09 AMShire licenses IBD candidate from Pfizer - Seeking Alpha
06/13/16 05:56 PMFDA tags two of Shire's GI candidates Breakthrough Therapies
06/13/16 09:21 AMAnalysts Observable Stocks: Gilead Sciences, Inc. (NASDAQ:GILD) , Shire plc (NASDAQ:SHPG) - Street Updates
06/12/16 09:02 AMShire (SHPG) Says Decentralized Procedure for Immunoglobulin Treatment Cuvitru in Europe Now Complete
06/12/16 09:02 AMBuy, Sell Or Hold Rating For Shire Plc (NASDAQ:SHPG)?
06/12/16 09:02 AMShort Interest in Shire PLC (SHPG) Rises By 26
06/10/16 02:19 PMShire announces completion of ... - [at noodls] - June 10, 2016 Cuvitru (IG 20mg/ml solution for subcutaneous injection) builds on company's broad portfolio of IG treatments gained through combination with Baxalta New option to treat primary and certain ...
06/10/16 09:25 AMNoteworthy Analysts Suggestions: Envision Healthcare Holdings, Inc. (NYSE:EVHC) , Shire plc (NASDAQ:SHPG) - Street Updates
06/09/16 06:53 PMBest Stocks for Investors: State Street Corporation (NYSE:STT), Shire plc (NASDAQ:SHPG) - Beacon Chronicle
06/09/16 06:53 PMHot Stock seeking Investors: Shire plc (SHPG) - News Oracle
06/09/16 09:26 AMCan Shire plc (NASDAQ:SHPG) Meet Analysts Expectations? - Stocks Daily
06/08/16 06:54 PMNoteworthy Analyst's Rating to Observe: Shire plc (NASDAQ:SHPG) , EXACT Sciences Corporation (NASDAQ:EXAS) - Street Updates
06/08/16 06:54 PMInvestor Catching Stock: Shire plc (NASDAQ:SHPG) - News Oracle
06/07/16 06:39 PMAnalyst Opinion of: Shire plc (NASDAQ:SHPG) - News Oracle
06/07/16 06:39 PMAnalyst's Checklist Stocks: Vascular Biogenics Ltd. (NASDAQ:VBLT) , Shire plc (NASDAQ:SHPG) - Street Updates
06/06/16 06:30 PMStock's Earnings Activity: Sarepta Therapeutics, Inc. (NASDAQ:SRPT), Shire plc (NASDAQ:SHPG) - Beacon Chronicle
06/06/16 04:20 PMSHIRE PLC Files SEC form 8-K, Other Events, Financial Statements and Exhibits -
About Shire PLC

Shire PLC logoShire plc is a biotech company. The Company, along with its subsidiaries, is engaged in developing and marketing medicines for patients with rare diseases and other select conditions. The Company operates in the segment of research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. The Company focuses its development resources on projects in various therapeutic areas (TAs), including rare diseases, neuroscience, ophthalmics, hematology and gastrointestinal (GI), and focuses its early development projects primarily on rare diseases. Its products include VYVANSE/VENVANSE/ELVANSE/TYVENSE/ELVANSE VUXEN/ADUVANZ, ADDERALL XR, INTUNIV, LIALDA (mesalamine)/MEZAVANT(mesalazine), PENTASA (mesalamine), REPLAGAL (agalsidase alfa), ELAPRASE (idursulfase), VPRIV (velaglucerase alfa), FIRAZYR (icatibant), CINRYZE C1 esterase inhibitor (human), GATTEX/REVESTIVE, NATPARA/NATPAR, FOSRENOL (lanthanum carbonate) and KALBITOR.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Drug Manufacturers - Major
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: SHPG
  • CUSIP:
Key Metrics:
  • Previous Close: $180.66
  • 50 Day Moving Average: $180.04
  • 200 Day Moving Average: $176.53
  • P/E Ratio: 27.15
  • P/E Growth: 1.16
  • Market Cap: $35.63B
  • Current Quarter EPS Consensus Estimate: $12.55 EPS
Additional Links:
Shire PLC (NASDAQ:SHPG) Chart for Thursday, June, 30, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha